EU Fails to Address Smoking with Global Health Strategy

Dec.06.2022
EU Fails to Address Smoking with Global Health Strategy
The EU's global health strategy ignored e-cigarettes, drawing criticism from experts and consumer groups. A new tax plan raises concerns.

On December 5th, the European Commission (EC) announced its "Global Health Strategy" which aims to prioritize tackling the root causes of poor health. However, the strategy failed to address the issue of smoking through means of reducing tobacco harm.


The director of the World Vapers' Alliance (WVA), Michael Landl, has emphasized that the European Union (EU) has disregarded the science behind electronic cigarettes.


He stated: "The European Commission has once again ignored the voices of science and consumers. Reducing tobacco harm must be a key element of all EU health policies. 700,000 people die each year from smoking, while the Commission fights against less harmful alternatives. Science is clear that the harm of electronic cigarettes is much lower than smoking and they are one of the most effective smoking cessation aids. Consumers are demanding that the Commission finally accept this reality.


Meanwhile, in light of potential backlash against European Union efforts to reduce smoking rates, the EU has leaked a draft plan to increase taxes on electronic cigarette products, causing concern among the public. Experts in tobacco harm reduction and consumer groups have emphasized that such a tax would not only have adverse effects on public health, but could also create a large-scale new black market for electronic cigarette products.


The committee claims that increasing taxes will improve public health, but the facts say the opposite. Ordinary smokers trying to quit must be able to afford a less harmful substitute such as e-cigarettes. If the committee wants to mitigate the burden of smoking on public health, they must make e-cigarettes more affordable and accessible, not less," said Michael Landl, director of the World Vapers' Alliance (WVA).


2FIRSTS will continue to cover this topic, with updates available on the '2FIRSTSAPP.' Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
The U.S. Food and Drug Administration has told vape manufacturer Fontem US that it does not presently intend to take enforcement action against the company’s Zone nicotine pouches while litigation over the agency’s handling of the application remains unresolved.
Apr.07 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Special Report | China’s New Five-Year Plan Highlights “Health-First” Strategy, Providing Policy Context for Tobacco Sector
Special Report | China’s New Five-Year Plan Highlights “Health-First” Strategy, Providing Policy Context for Tobacco Sector
China’s 2026 “Two Sessions” reviewed the draft Outline of the 15th Five-Year Plan, which proposes implementing a health-first development strategy and strengthening the effectiveness of the Patriotic Health Campaign. Although the document does not address specific industries, this public-health governance framework provides a new policy context for observing the future regulation, product strategies, and market development of China’s tobacco and next-generation nicotine sectors.
Industry Insight
Mar.08
GEEK BAR to Return to the European Market: Launches the SPARK Pod System
GEEK BAR to Return to the European Market: Launches the SPARK Pod System
GEEK BAR announced its return to the European market and the release of its pod-based product, SPARK, which will begin rolling out across select European countries starting in March. SPARK features a battery-status display interface and a fast-charging battery. It offers a 1.1Ω prefilled pod (up to approximately 1,000 puffs) and a 0.8Ω refillable pod, along with multiple new flavors tailored for Europe.
Mar.04 by 2FIRSTS.ai
HB337 Moves Forward: Cigarette and Nicotine Taxes Set to Rise in Utah
HB337 Moves Forward: Cigarette and Nicotine Taxes Set to Rise in Utah
Utah lawmakers are advancing HB337, a bill that would raise the state cigarette tax by $2 per pack and restructure taxes on other nicotine products. The proposal replaces weight-based taxes with percentage-based rates and removes reduced rates for certain modified risk products. Supporters say it will curb youth tobacco use, while opponents warn of cross-border shopping and harm to consumers seeking alternatives.
Feb.17
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24